论文部分内容阅读
目的 :探讨螺内酯对急性心肌梗死 (AMI)后血浆Ⅲ型前胶原氨基末端肽 (PⅢNP)的影响。方法 :将6 0例前壁AMI患者随机分为两组 ,对照组采用常规治疗 ,治疗组在常规治疗基础上口服螺内酯 2 5mg ,bid。两组均在入院后第 1、7、2 8、6 0天采血检测PⅢNP含量。结果 :AMI后血清PⅢNP增加 ,与正常人PⅢNP水平相比差异有统计学意义 [(3.2 4± 2 .13)∶(2 .12± 1.78) μg/L ,P <0 .0 5 ]。治疗第 2 8天后 ,治疗组PⅢNP水平明显低于对照组 [(4 .78± 2 .0 1)∶(5 .98± 2 .6 5 ) μg/L ,P <0 .0 5 ]。结论 :在AMI后早期使用螺内酯治疗可以降低PⅢNP含量 ,减少Ⅲ型胶原的产生。
Objective: To investigate the effect of spironolactone on plasma type Ⅲ procollagen aminoterminal peptide (PⅢNP) after acute myocardial infarction (AMI). Methods: Sixty AMI patients with anterior wall were randomly divided into two groups. The control group received routine treatment. The treatment group received oral spironolactone 2.5 mg bid on the basis of routine treatment. Blood samples were collected on the 1st, 7th, 20th, 20th and 60th day after admission for detection of PⅢNP levels in both groups. Results: The serum PⅢNP increased after AMI, which was significantly different from that of PⅢNP in normal subjects [(3.2 4 ± 2.13) vs (2.12 ± 1.78) μg / L, P <0.05). After 28 days of treatment, the level of PⅢNP in the treatment group was significantly lower than that in the control group [(4.78 ± 2.01) :( 5.98 ± 2.56) μg / L, P <0.05). Conclusions: The use of spironolactone early after AMI can reduce the content of PⅢNP and reduce the production of type Ⅲ collagen.